Log in

Webinar 3 - Update on bipolar disorder

October 22, 2020 (19:00, UTC+2)

Global Times
10:00 (Los Angeles), 13:00 (New York), 18:00 (London), 19:00 (Paris), 2:00, Oct 23 (Tokyo)

Allan Young (United Kingdom)
Presentation Title:
God’s Mood Stabiliser: Latest Data on Lithium

Katherine Burdick (USA)
Presentation Title:
Cognitive Decline In Bipolar Disorder: Can We Prevent It?

Pierre Blier (Canada)

Registration Fees per Webinar

  • CINP Member - $20
  • CINP Non-Member - $40
  • Student, Trainee, Fellow - $0 (Proof of student or post doc status is required at time of registration.)

Join the conversation online on Facebook, LinkedIn, or Twitter using our official hashtag: #CINPOnline

Allan Young, United Kingdom (Speaker)

Professor Allan Young is Chair of Mood Disorders and Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, where he is also interim Vice-Dean for Academic Psychiatry. Professor Young is the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) Cluster and Theme Lead in the Translational Therapeutics Cluster. He is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust, where he is also Consultant Psychiatrist and Head of the Affective Disorders Service.

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grants from several funding agencies and has over 500 peer-reviewed publications, including several books about psychopharmacology and affective disorders.

He is immediate past President of the International Society for Affective Disorders, past President of the British Association of Psychopharmacology and immediate past Chair of the Special Committee for Psychopharmacology of the Royal College of Psychiatrists. He is also a trustee of the patient and family charity Bipolar UK, and of the Drug Safety Research Unit (DSRU), internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.

Katherine Burdick, USA (Speaker)

Dr. Katherine E. Burdick is an Associate Professor of Psychology in Psychiatry at Harvard Medical School. She is the Director of the Mood and Psychosis Research Program and the Associate Vice Chair for Research in Psychiatry at Brigham and Women’s Hospital in Boston, MA. She has expertise in clinical and neurocognitive assessment across a range of patients with serious mental illness, including schizophrenia and bipolar disorder.

Dr. Burdick obtained her Ph.D. in Clinical Neuropsychology from the City University of New York-The Graduate Center and completed her clinical internship and her postdoctoral fellowship at Yale University School of Medicine. She is a licensed clinical psychologist in the state of NY.

Dr. Burdick has a strong track record of both federal and foundation funding, with a primary research focus on identifying persistent cognitive deficits in major psychiatric disorders, understanding their etiologies, and directly targeting them with treatment. She has collaborated on a wide range of projects including neuroimaging, genetics, and treatment trials in patients with bipolar disorder, schizophrenia, and major depression and has authored more than 130 peer-reviewed publications in this area.

Pierre Blier, Canada (Moderator)

Dr Pierre Blier is a Full Professor for the Departments of Psychiatry and Cellular & Molecular Medicine in the Faculty of Medicine at the University of Ottawa in Ottawa, Ontario, Canada, and the Director of the Mood Disorders Research Unit at The Royal’s Institute of Mental Health Research.
Dr Blier is on the editorial boards of several journals and is the co-editor in chief for the Journal of Psychopharmacolgy.  In addition to his extensive list of publications and lectures presented worldwide, Dr. Blier has contributed to several treatment guidelines for psychiatric disorders. Dr Blier has a basic research laboratory investigating how psychotropic medications work in the brain, he carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis.
Dr Blier received several awards for outstanding contributions to psychopharmacology including the Canada Research Chair in Psychopharmacology from the Government of Canada and is now a Fellow of the Royal Society of Canada (Life Sciences). He also serves on several committees, including the presidency elect of the CINP.

©2021 CINP